A new study suggests that Terns Pharmaceuticals’ targeted leukemia drug may be a successor to Novartis’ blockbuster treatment. The research showed that the medication maintained and even boosted high molecular response rates in advanced-stage patients, providing promising results for its potential as a next-generation therapy.
Source: https://www.statnews.com/2025/12/08/ash-positive-results-leukemia-terns-rival-novartis